The earnings call highlighted significant achievements, particularly in international market growth and record-breaking profitability. Despite a decline in Canadian recreational revenue and increased SG&A expenses, the company's robust financial position and operational efficiency improvements suggest a positive outlook.

Company Guidance

During the Aurora Cannabis Inc. third quarter 2025 conference call, significant guidance and metrics were provided, highlighting a record-breaking quarter. Aurora reported a 37% increase in net revenue, reaching $88.2 million, driven by 51% year-over-year growth in global medical cannabis revenue, with international revenue increasing by 112%. Medical cannabis comprised 77% of total net revenue, contributing 90% of the adjusted gross profit, while the adjusted gross margin hit a record 65%. The company achieved an all-time high in adjusted EBITDA, growing 316% to $23.1 million. Moreover, net income reached $31.2 million, reversing a loss from the previous year, and the company generated $27.4 million in positive free cash flow. Aurora's balance sheet remains strong with $180.2 million in cash and cash equivalents and no cannabis business debt, positioning it well for future growth opportunities in international medical cannabis markets.

Record-Breaking Revenue and Profitability

The company reported a record third quarter for medical cannabis revenue, net income, adjusted EBITDA, and free cash flow. Overall net revenue grew 37%, with international medical cannabis revenue increasing 112% year-over-year.

Strong International Performance

International revenue surpassed Canadian medical cannabis revenue for the second consecutive quarter, comprising 60% of global medical cannabis net revenue. Revenue in Australia and the UK reached record levels this quarter.

All-time High in Adjusted EBITDA

Adjusted EBITDA grew 316% to a record $23.1 million, marking the ninth consecutive quarter of positive adjusted EBITDA.

Robust Financial Position

The company ended the quarter with $180.2 million in cash and cash equivalents and no cannabis business debt.

Operational Efficiency and Margin Improvement

Adjusted gross margin for medical cannabis increased to 74% from 63% in the year-ago period, driven by sustainable cost reductions and improved manufacturing efficiency.

---

Aurora Cannabis (ACB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ACB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jun 19, 2025	2025 (Q4)	0.08 / -	-0.282	―	―	―
Feb 05, 2025	2025 (Q3)	<0.01 / 0.40	-0.352	214.00% (+0.75)
Nov 06, 2024	2025 (Q2)	-0.08 / -0.15	0	―
Aug 07, 2024	2025 (Q1)	-0.12 / 0.06	-0.563	110.00% (+0.62)
Jun 20, 2024	2024 (Q4)	-0.13 / -0.28	9.596	-102.94% (-9.88)
Feb 08, 2024	2024 (Q3)	-0.09 / -0.35	-1.761	80.00% (+1.41)
Nov 09, 2023	2024 (Q2)	- / 0.00	-1.408	―
Sep 26, 2023	2023 (Q4)	- / -	-0.12	―	―	―
Aug 10, 2023	2024 (Q1)	-0.37 / -0.56	-1.197	52.94% (+0.63)
Jun 14, 2023	2023 (Q3)	-0.28 / 9.60	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

ACB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 05, 2025	$3.68	$5.37	+45.92%
Nov 06, 2024	$6.11	$5.12	-16.20%
Aug 07, 2024	$5.88	$6.25	+6.29%
Jun 20, 2024	$5.72	$5.52	-3.50%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---